WT1

You have access
Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Resection: A Phase I/IIa Clinical Trial
KAZUHIRO NAGAI, TOMOHIKO ADACHI, HIROSHI HARADA, SUSUMU EGUCHI, HARUO SUGIYAMA and YASUSHI MIYAZAKI

Anticancer Research October 2020, 40 (10) 5765-5776; DOI: https://doi.org/10.21873/anticanres.14593
You have access
WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study
RYU YANAGISAWA, TOMONOBU KOIZUMI, TERUTSUGU KOYA, KENJI SANO, SHIGEO KOIDO, KAZUHIRO NAGAI, MASANORI KOBAYASHI, MASATO OKAMOTO, HARUO SUGIYAMA and SHIGETAKA SHIMODAIRA

Anticancer Research April 2018, 38 (4) 2217-2225;
You have access
Immunohistochemical Analysis of WT1 Antigen Expression in Various Solid Cancer Cells
KEIKO NAITOH, TAKASHI KAMIGAKI, ERIKO MATSUDA, HIROSHI IBE, SACHIKO OKADA, ERI OGUMA, YOSHIHIRO KINOSHITA, RISHU TAKIMOTO, KAORI MAKITA, SHUN OGASAWARA and SHIGENORI GOTO

Anticancer Research July 2016, 36 (7) 3715-3724;
You have access
Prognostic Markers for Patient Outcome Following Vaccination with Multiple MHC Class I/II-restricted WT1 Peptide-pulsed Dendritic Cells Plus Chemotherapy for Pancreatic Cancer
KAZUKI TAKAKURA, SHIGEO KOIDO, SHIN KAN, KOSAKU YOSHIDA, MASAKO MORI, YUTA HIRANO, ZENSHO ITO, HIROKO KOBAYASHI, SHINICHIRO TAKAMI, YOSHIHIRO MATSUMOTO, MIKIO KAJIHARA, TAKEYUKI MISAWA, MASATO OKAMOTO, HARUO SUGIYAMA, SADAMU HOMMA, TOSHIFUMI OHKUSA and HISAO TAJIRI

Anticancer Research January 2015, 35 (1) 555-562;
You have access
Immunogenic Modulation of Cholangiocarcinoma Cells by Chemoimmunotherapy
SHIGEO KOIDO, SHIN KAN, KOSAKU YOSHIDA, SHINJI YOSHIZAKI, KAZUKI TAKAKURA, YOSHIHISA NAMIKI, SHINTARO TSUKINAGA, SHUNICHI ODAHARA, MIKIO KAJIHARA, MASATO OKAMOTO, MASAKI ITO, SEI-ICHI YUSA, JIANLIN GONG, HARUO SUGIYAMA, TOSHIFUMI OHKUSA, SADAMU HOMMA and HISAO TAJIRI

Anticancer Research November 2014, 34 (11) 6353-6361;
You have access
High Levels of Wilms' Tumor 1 (WT1) Expression Were Associated with Aggressive Clinical Features in Ovarian Cancer
ZHIYANG LIU, KEIKO YAMANOUCHI, TSUYOSHI OHTAO, SOHEI MATSUMURA, MANABU SEINO, VIJI SHRIDHAR, TOSHIFUMI TAKAHASHI, KAZUHIRO TAKAHASHI and HIROHISA KURACHI

Anticancer Research May 2014, 34 (5) 2331-2340;
You have access
Correlation of Wilms' Tumor 1 Isoforms with HER2 and ER-α and its Oncogenic Role in Breast Cancer
TAPANAWAN NASOMYON, SRILA SAMPHAO, SURASAK SANGKHATHAT, SOMRIT MAHATTANOBON and POTCHANAPOND GRAIDIST

Anticancer Research March 2014, 34 (3) 1333-1342;
You have access
Wilms' Tumor 1 Is Involved in Tumorigenicity of Glioblastoma by Regulating Cell Proliferation and Apoptosis
NORIYUKI KIJIMA, NAOKI HOSEN, NAOKI KAGAWA, NAOYA HASHIMOTO, MANABU KINOSHITA, YUSUKE OJI, HARUO SUGIYAMA and TOSHIKI YOSHIMINE

Anticancer Research January 2014, 34 (1) 61-67;
You have access
Wilms' Tumor Gene 1 (WT1) – loaded Dendritic Cell Immunotherapy in Patients with Uterine Tumors: A Phase I/II Clinical Trial
AN COOSEMANS, ANKE VANDERSTRAETEN, SANDRA TUYAERTS, TINA VERSCHUERE, PHILIPPE MOERMAN, ZWI N. BERNEMAN, IGNACE VERGOTE, FRÉDÉRIC AMANT and STEFAAN W. VAN GOOL

Anticancer Research December 2013, 33 (12) 5495-5500;
You have access
Immunological Response after WT1 mRNA-loaded Dendritic Cell Immunotherapy in Ovarian Carcinoma and Carcinosarcoma
AN COOSEMANS, ANKE VANDERSTRAETEN, SANDRA TUYAERTS, TINA VERSCHUERE, PHILIPPE MOERMAN, ZWI BERNEMAN, IGNACE VERGOTE, FRÉDÉRIC AMANT and STEFAAN W. VAN GOOL

Anticancer Research September 2013, 33 (9) 3855-3859;

Main menu

User menu

Search

WT1